|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SORCS1 |
Gene summary for SORCS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SORCS1 | Gene ID | 114815 |
| Gene name | sortilin related VPS10 domain containing receptor 1 | |
| Gene Alias | hSorCS | |
| Cytomap | 10q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KVZ0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 114815 | SORCS1 | S014 | Human | Liver | HCC | 6.02e-18 | 7.52e-01 | 0.2254 |
| 114815 | SORCS1 | S015 | Human | Liver | HCC | 3.17e-08 | 3.87e-01 | 0.2375 |
| 114815 | SORCS1 | S016 | Human | Liver | HCC | 8.57e-24 | 8.21e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:000689221 | Liver | HCC | post-Golgi vesicle-mediated transport | 77/7958 | 104/18723 | 6.14e-11 | 2.24e-09 | 77 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SORCS1 | SNV | Missense_Mutation | novel | c.1828N>A | p.Leu610Ile | p.L610I | Q8WY21 | protein_coding | tolerated(0.12) | benign(0.408) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SORCS1 | SNV | Missense_Mutation | novel | c.3071N>A | p.Val1024Glu | p.V1024E | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-AO-A0J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| SORCS1 | SNV | Missense_Mutation | rs773862245 | c.3475N>T | p.Arg1159Trp | p.R1159W | Q8WY21 | protein_coding | deleterious_low_confidence(0.03) | benign(0.352) | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| SORCS1 | SNV | Missense_Mutation | c.2460N>C | p.Met820Ile | p.M820I | Q8WY21 | protein_coding | tolerated(0.87) | benign(0.006) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SORCS1 | SNV | Missense_Mutation | rs369334370 | c.1159C>T | p.Arg387Trp | p.R387W | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| SORCS1 | SNV | Missense_Mutation | c.1846G>A | p.Glu616Lys | p.E616K | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SORCS1 | SNV | Missense_Mutation | rs367597399 | c.277C>T | p.Arg93Trp | p.R93W | Q8WY21 | protein_coding | deleterious_low_confidence(0.01) | benign(0.075) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| SORCS1 | insertion | Frame_Shift_Ins | novel | c.2684_2685insAGGGACAGAAGCTCAATTCACGCTG | p.Ser896GlyfsTer87 | p.S896Gfs*87 | Q8WY21 | protein_coding | TCGA-B6-A0IB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SORCS1 | deletion | Frame_Shift_Del | novel | c.1893delT | p.Phe631LeufsTer16 | p.F631Lfs*16 | Q8WY21 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SORCS1 | SNV | Missense_Mutation | novel | c.3305C>T | p.Ala1102Val | p.A1102V | Q8WY21 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |